50,000 Shares in Novo Nordisk A/S $NVO Bought by Truffle Hound Capital LLC

Truffle Hound Capital LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $2,774,000. Novo Nordisk A/S accounts for about 0.8% of Truffle Hound Capital LLC’s portfolio, making the stock its 27th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. SG Americas Securities LLC grew its stake in shares of Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after purchasing an additional 2,274,925 shares during the period. Bank of Montreal Can lifted its position in Novo Nordisk A/S by 101.4% during the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock worth $170,845,000 after buying an additional 1,246,467 shares in the last quarter. DAVENPORT & Co LLC lifted its position in shares of Novo Nordisk A/S by 54.8% during the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after purchasing an additional 935,468 shares in the last quarter. Sustainable Growth Advisers LP increased its holdings in shares of Novo Nordisk A/S by 11.7% in the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after purchasing an additional 649,390 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Novo Nordisk A/S by 42.6% during the second quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock worth $101,920,000 after acquiring an additional 441,034 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NVO shares. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Citigroup started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $49.59 on Friday. The stock has a market capitalization of $221.43 billion, a price-to-earnings ratio of 14.29 and a beta of 0.67. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The firm has a fifty day simple moving average of $53.74 and a 200 day simple moving average of $53.23. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Berenberg maintained its Buy rating on Novo Nordisk, reinforcing investor confidence in the company’s growth outlook and valuation support from a respected European bank. Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
• Positive Sentiment: IQVIA data show Wegovy oral-pill prescriptions hitting ~38,220 in week five post-launch, signaling strong early uptake for the new oral formulation and supporting near-term revenue momentum. Novo’s Wegovy pill tracks over 38,000 prescriptions in fifth week
• Positive Sentiment: Company update: Novo completed a Phase 3 study of oral semaglutide in youth diabetes care — a potential label expansion that could broaden the drug’s addressable market if approved. Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care
• Positive Sentiment: Legal/market protection: U.S. officials may act against Hims after its attempted sale of a compounded Wegovy copy, which could help defend Novo’s IP and commercial position. US could take action including fines against Hims after brief Wegovy copy launch
• Positive Sentiment: Product strategy: Novo plans to introduce Wegovy in vial presentations (and other device formats), a move to improve access, pricing flexibility and supply resiliency amid competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: Usage trend: A study finds many Wegovy pill users are new to GLP‑1s, suggesting the product is bringing first‑time patients into the class and expanding market demand. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Company expansion: Coverage on Novo’s broader global healthcare initiatives highlights long‑term growth avenues but is less likely to move near‑term sentiment. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Industry context: A CNBC piece on pharma’s “reset” around pricing and pipelines frames regulatory and pricing headwinds that apply across the sector. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive landscape: Analysis comparing Eli Lilly and Novo Nordisk underscores intense competition in a rapidly growing weight‑loss market; investors should watch share trends and margin pressure. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market
• Negative Sentiment: Regulatory/legal risk: Coverage about FDA warnings and potential lawsuits tied to Wegovy highlights an ongoing downside risk to valuation if safety signals or litigation escalate. FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.